Arvinas Appoints Randy Teel as President, CEO, and Director

Arvinas, a biotechnology company, has appointed Randy Teel, Ph.D. as president, CEO, and director. The company focuses on developing therapies that degrade disease-causing proteins through its PROTAC Discovery Engine platform. Its clinical-stage programs include vepdegestrant for breast cancer, ARV-766 and bavdegalutamide for prostate cancer, and ARV-102 for neurodegenerative disorders. The company's product candidate, ARV-393, targets the B-cell lymphoma 6 protein.